Last reviewed · How we verify
Triac
At a glance
| Generic name | Triac |
|---|---|
| Also known as | Tiratricol, Téatrois, TA3 |
| Sponsor | Erasmus Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate (NA)
- Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients (PHASE2)
- Ketogenic Diet Interventions in Parkinson's Disease: Safeguarding the Gut Microbiome (NA)
- A Study to Explore if Long-term Use of Mucinex Can Help With Symptoms in Patients With Stable Chronic Bronchitis. (PHASE4)
- Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication. (NA)
- Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency
- A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus (PHASE3)
- Triac Trial II in MCT8 Deficiency Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triac CI brief — competitive landscape report
- Triac updates RSS · CI watch RSS
- Erasmus Medical Center portfolio CI